Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.65 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26546756 | 0.89 | KDR (0.76) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL29476070 | 0.87 | KDR (0.68) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL2350751 | 0.87 | KDR (0.68) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL13004812 | 0.86 | KDR (0.71) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL4443052 | 0.86 | KDR (0.71) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL27420134 | 0.86 | LMNA (0.63) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL9365319 | 0.85 | KDR (0.66) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL5804247 | 0.85 | KDR (0.69) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL14422910 | 0.85 | KDR (0.69) | KDRKCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL28884494 | 0.85 | KDR (0.69) | KDRKCNJ5KCNJ3LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824581-B | Alanine-containing peptide-like compound and preparation method and application thereof | 西安交通大学 | 2020-08-18 | — | — | CN | disclosed |
| CN-109651243-B | Serine-containing peptoid compound and preparation method and application thereof | 西安交通大学 | 2020-05-22 | — | — | CN | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | KDR 735/4885CYP3A4 902/4885KCNJ5 2301/4885 |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | KDR 31/4885CYP3A4 4465/4885KCNJ5 1283/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | KDR 719/4885CYP3A4 3146/4885KCNJ5 1584/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | KDR 31/4885CYP3A4 4465/4885KCNJ5 1283/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | KDR 2433/4885CYP3A4 3712/4885KCNJ5 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.